GlassScriptPhysician profile
Matthew M Merrell
NPI 1346291259
$6,274.49
in general payments reported to CMS, 2019-2025
47 companies · $1,245 in 2025
The $1,245 reported for 2025 was more than what a typical Urology provider received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,054 · 2020: $376 · 2021: $927 · 2022: $761 · 2023: $1,140 · 2024: $771 · 2025: $1,245.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,064 · Education: $91.47.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,064.41 |
| Education | $91.47 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $1,092.29 | 2019-2025 | Xtandi, Myrbetriq, Veozah |
| Coloplast Corp | $716.66 | 2019-2024 | Titan |
| Janssen Biotech, INC. | $693.94 | 2019-2025 | Erleada, Akeega, Rybrevant |
| Endo Pharmaceuticals INC. | $274.95 | 2019-2024 | Xiaflex, Aveed |
| Novartis Pharmaceuticals Corporation | $269.80 | 2022-2025 | |
| Dendreon Pharmaceuticals LLC | $267.61 | 2019-2025 | Provenge |
| Abbvie INC. | $253.94 | 2023-2025 | |
| Merck Sharp & Dohme LLC | $230.82 | 2022-2025 | Keytruda, Lynparza, Welireg |
| Sumitomo Pharma America, INC. | $230.34 | 2023-2025 | Orgovyx, Gemtesa |
| Boston Scientific Corporation | $218.50 | 2020-2025 | Spaceoar Vue System - 10ml, General - Kidney Stone Disease |
| Pfizer INC. | $194.33 | 2019-2025 | |
| Urogen Pharma, INC. | $179.83 | 2021-2025 | Jelmyto |
| Allergan, INC. | $177.89 | 2019-2021 | |
| Myriad Genetic Laboratories, INC. | $150.34 | 2022-2025 | Prolaris |
| Teleflex LLC | $113.08 | 2021-2025 | Barrigel, Urolift |
Show all 46 companies
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Matthew Merrell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.